US Biopharmaceutical Company Liminatus Pharma Plans to Raise $500 Million to Invest in BNB

July 28th. As per a report from businessinsider, the clinical-stage biopharmaceutical company Liminatus Pharma, Inc. (NASDAQ: LIMN) announced today that it has planned to strategically expand into the cryptocurrency and blockchain domain. The company intends to set up a subsidiary named "American BNB Strategy" to take the lead in its digital asset investment and management scheme. By means of this platform, Liminatus plans to gradually raise and allocate up to $500 million in funds, with the aim of making strategic long-term investments in BNB. Liminatus stressed that although the company remains fully dedicated to its core business - advancing cancer treatments and pancreatic cancer diagnostic technologies, expanding into the digital asset space is regarded as a necessary measure to support long-term growth and enhance shareholder value. Liminatus is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies for cancer patients. The company is progressing a series of novel therapies targeting cancer antigens and tumor-specific immune responses.